Optiscan has been featured in StockwireX regarding the halfway recruitment milestone in its first in-human breast cancer imaging study at The Royal Melbourne Hospital (RMH).

The article highlights that 25 of the target 50 patients have been recruited and imaged as of 4 June 2026, with the milestone keeping the company on schedule for U.S. FDA submissions for both its InVue® and InForm® devices, targeted for H2 CY2026.

“The study also has another benefit for Optiscan over and above its demonstration of the clinical importance of the Company’s medical technology. It will additionally make a valuable contribution to our efforts to deliver regulatory approvals, a core requirement in Optiscan’s plans to commercialise its product offering. The insights generated by this RMH study will definitely continue to inform our commercial strategy and support broader market adoption of our devices,” Dr Camile Farah, CEO and Managing Director, Optiscan Imaging.

Read the full article here.